Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7677772 | 0.93 | TSHR (0.42) | HIF1ATSHRMEN1KMT2AFAAH | |
| SCHEMBL2387722 | 0.84 | MEN1 (0.43) | HIF1ATSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL7172974 | 0.75 | TSHR (0.42) | TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL93269 | 0.75 | ADH1B (0.48) | MEN1KMT2AALDH1A1 | |
| SCHEMBL1314528 | 0.74 | MEN1 (0.56) | TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL6663432 | 0.74 | MEN1 (0.56) | MEN1KMT2A | |
| SCHEMBL7673174 | 0.71 | HIF1A (0.39) | HIF1ATSHRFAAHTRPV1ALDH1A1 | |
| SCHEMBL2970306 | 0.70 | MEN1 (0.46) | MEN1KMT2A | |
| SCHEMBL1751213 | 0.70 | — | — | |
| SCHEMBL27329689 | 0.70 | MEN1 (0.40) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104557561-A | Method for preparing N1,N1-diisoprylamino ethylamine or salts of N1,N1-diisoprylamino ethylamine | BEIJING YUEKANGKECHUANG MEDICAL TECHNOLOGY CO LTD | 2015-04-29 | — | — | CN | claimed |
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | claimed |
| EP-1001943-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2000-05-24 | — | — | EP | claimed |
| WO-1999003843-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1999-01-28 | — | — | WO | claimed |
| US-20190298681-A1 | Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) and Related Diagnostics | MERRIMACK PHARMACEUTICALS, INC. | 2019-10-03 | — | — | US | disclosed |
| CN-104557561-B | A kind of preparation method of N1, N1-diisopropyl ethylenediamine or its salt | 北京悦康科创医药科技有限公司 | 2016-07-06 | — | — | CN | disclosed |
| CN-104557561-B | A kind of preparation method of N1, N1-diisopropyl ethylenediamine or its salt | 北京悦康科创医药科技有限公司 | 2016-07-06 | — | — | CN | disclosed |
| CN-104557561-A | Method for preparing N1,N1-diisoprylamino ethylamine or salts of N1,N1-diisoprylamino ethylamine | BEIJING YUEKANGKECHUANG MEDICAL TECHNOLOGY CO LTD | 2015-04-29 | — | — | CN | disclosed |
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | disclosed |
| EP-1001943-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999003843-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1999-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298681-A1 | Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) and Related Diagnostics | EPHA2, EPHB2, EPHB1 | HIF1A 1294/4885TSHR 1708/4885MEN1 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.